|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 401/12 | |
| A61K 31/415 | |||
| A61P 3/04 | |||
| C07D 213/72 | |||
| A61K 31/444 | |||
| A61K 45/06 |
| (11) | Number of the document | 2781516 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13197714.2 |
| Date of filing the European patent application | 2011-10-05 | |
| (97) | Date of publication of the European application | 2014-09-24 |
| (45) | Date of publication and mention of the grant of the patent | 2016-12-07 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 390888 P | 2010-10-07 | US |
| (72) |
Sutton, Paul, Allen, US
Girgis, Michael J., US
Liang, Jessica, US
Prashad, Mahavir, US
Villhauer, Edwin, Bernard, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid |
| New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid |